Rituximab - Wikipedia
Rituximab in dermatology | Actas Dermo-Sifiliográficas
Drug Insight: the mechanism of action of rituximab in autoimmune disease—the immune complex decoy hypothesis | Nature Reviews Rheumatology
Lessons for rituximab therapy in patients with rheumatoid arthritis - The Lancet Rheumatology
Rituximab in neurological disease: principles, evidence and practice | Practical Neurology
Role of biological agents in treatment of rheumatoid arthritis - ScienceDirect
B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience | Annals of the Rheumatic Diseases
PV | RITUXAN® (rituximab) Proposed Mechanism of Action (MoA)
Rituximab, an Anti‐CD20 Monoclonal Antibody: History and Mechanism of Action - Pescovitz - 2006 - American Journal of Transplantation - Wiley Online Library
Rituximab (Rituxan) | American Journal of Neuroradiology
JPM | Free Full-Text | Using the Immunophenotype to Predict Response to Biologic Drugs in Rheumatoid Arthritis
Targeting CD20: Monoclonals of the future - ppt download
The Risk of Hyperglycaemia with the use of Rituximab in Rheumatoid Arthritis. Results from a Meta-analysis of Randomised Clinica
Biological Therapy for Rheumatoid Arthritis - ppt download
Main mechanisms of action of rituximab and ways to increase its... | Download Scientific Diagram
Rituximab mode of action: apoptosis and ADCC. Rituximab mediated... | Download Scientific Diagram
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
Novel therapeutic targets in rheumatoid arthritis: Trends in Pharmacological Sciences
Rituximab-related Severe Toxicity | SpringerLink
B-Cell Targeted Therapies: Clinical Trials Update
Immunosuppressive therapy with rituximab in common variable immunodeficiency | Clinical and Molecular Allergy | Full Text
RA | RITUXAN® (rituximab) Proposed Mechanism of Action (MoA) in Rheumatoid Arthritis
Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial - The Lancet
Anti‐CD20 Antibody Rituximab in the Treatment of Rheumatoid Arthritis - Korhonen - 2010 - Basic & Clinical Pharmacology & Toxicology - Wiley Online Library
Mechanism of action of rituximab. Rituximab is a monoclonal antibody... | Download Scientific Diagram
